Net sales was above our expectation in Q2 but order book was down by 21% on y/y basis.
Redeye sees Q2 sales in line with our forecast but higher costs, prompting us to lower our 2024e EBI...
Q2 2024 profit before loan losses came in at DKK 63m, DKK 7m (10%) below our estimate.
Q2 production slightly below Focus in Q2: Exploration, FDP on Block 56 & strategic review P/NAV of 0...
Redeye comments on the published order of SEK 31m for OTS™ Hip stemming from the distribution agreem...
Redeye updates its estimates on Sleep Cycle following its Q2 2024 quarterly report, which matched ou...
Obducat publicerade den 26 juli 2024 bolagets delårsrapport för det andra kvartalet 2024, vilken vis...
Suominen’s Q2 results are due Aug 9. H1 has low comparison figures, while H2 should also have scope ...
Redeye updates on EG7 following the weaker-than-expected Q2-results which looks to be related to a c...
Føroya Banki reports its Q2 2024 results on 1 August 2024.
Servicebolaget Coor rapporterade ett andra kvartal som kom in något över Analysguidens prognos.
Redeye shares its initial comments on Xspray following the Dasynoc CRL.
Redeye has updated its estimates for Safeture following the Q2 2024 report, which was in line with o...
Redeye anticipates a muted Q2 2024 in terms of quarter-on-quarter growth, though stable ARR growth i...
Net sales and clean EBIT were in line with consensus but the share price declined by 7.
Redeye is happy to see that Impact Coatings has received another order for an IC2000 fuel cell coati...
Redeye comments on EG7’s announcement of preliminary Q2-results which are below our expectations.
Sales down 20% y-o-y in Q2 More restructuring in the quarter Overall market has likely trouged Q2: ...
Kinda Brave Entertainment Group AB (”Kinda Brave” eller ”Koncernen”) meddelade den 25 juli år 2024 a...
Redeye leaves a note following Alzinova’s announcement of Carol Routledge having been appointed as t...